BR112012003571A2 - método para melhorar e para avaliar a capacidade de fabricação de uma imunoglobina, método para preparar uma imunoglobulina, e, imunoglobulina variante. - Google Patents

método para melhorar e para avaliar a capacidade de fabricação de uma imunoglobina, método para preparar uma imunoglobulina, e, imunoglobulina variante.

Info

Publication number
BR112012003571A2
BR112012003571A2 BR112012003571A BR112012003571A BR112012003571A2 BR 112012003571 A2 BR112012003571 A2 BR 112012003571A2 BR 112012003571 A BR112012003571 A BR 112012003571A BR 112012003571 A BR112012003571 A BR 112012003571A BR 112012003571 A2 BR112012003571 A2 BR 112012003571A2
Authority
BR
Brazil
Prior art keywords
immunoglobulin
evaluating
enhancing
preparing
variant
Prior art date
Application number
BR112012003571A
Other languages
English (en)
Inventor
Andreas Arnell
Jesús Zurdo
José Jiménez
Rebeca Michael
Yvette Stallwood
Original Assignee
Lonza Biologics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012003571(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lonza Biologics Plc filed Critical Lonza Biologics Plc
Publication of BR112012003571A2 publication Critical patent/BR112012003571A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012003571A 2009-08-21 2010-08-20 método para melhorar e para avaliar a capacidade de fabricação de uma imunoglobina, método para preparar uma imunoglobulina, e, imunoglobulina variante. BR112012003571A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0914691.1A GB0914691D0 (en) 2009-08-21 2009-08-21 Immunoglobulin variants
US24171709P 2009-09-11 2009-09-11
PCT/GB2010/001579 WO2011021009A1 (en) 2009-08-21 2010-08-20 Variant immunoglobulins with improved manufacturability

Publications (1)

Publication Number Publication Date
BR112012003571A2 true BR112012003571A2 (pt) 2016-11-22

Family

ID=41171774

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003571A BR112012003571A2 (pt) 2009-08-21 2010-08-20 método para melhorar e para avaliar a capacidade de fabricação de uma imunoglobina, método para preparar uma imunoglobulina, e, imunoglobulina variante.

Country Status (16)

Country Link
US (2) US8951516B2 (pt)
EP (1) EP2467400B1 (pt)
JP (1) JP5901522B2 (pt)
KR (1) KR20120056850A (pt)
CN (2) CN102596994A (pt)
AU (1) AU2010284841A1 (pt)
BR (1) BR112012003571A2 (pt)
CA (1) CA2771465A1 (pt)
DK (1) DK2467400T3 (pt)
EA (1) EA201290063A1 (pt)
GB (1) GB0914691D0 (pt)
IL (1) IL217993A0 (pt)
MX (1) MX2012002100A (pt)
SG (2) SG10201404903XA (pt)
TW (1) TW201116626A (pt)
WO (1) WO2011021009A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
MX371442B (es) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP3209684B1 (en) * 2014-10-24 2020-12-23 F.Hoffmann-La Roche Ag Vh-vl-interdomain angle based antibody humanization
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
SG10202006863YA (en) 2015-02-16 2020-08-28 Lonza Ag Cl and/or ch1 mutated antibodies for drug conjugation
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
US10590199B2 (en) * 2016-06-29 2020-03-17 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3765494A4 (en) 2018-03-15 2022-03-23 Chugai Seiyaku Kabushiki Kaisha ANTI-DENGUE VIRUS ANTIBODIES WITH CROSS-REACTIVITY AGAINST ZIKA VIRUS AND METHODS OF USE
EP3772518A1 (en) * 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
WO2022147463A2 (en) * 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ES2694002T3 (es) * 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1627046A4 (en) 2003-05-06 2008-02-13 Scripps Research Inst DOMAIN EXCHANGE BINDING MOLECULES, METHODS OF USE AND METHODS OF PRODUCTION
EP1660655B1 (en) * 2003-06-27 2016-11-02 Bioren, LLC Look-through mutagenesis
CN1898267B (zh) * 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
GB0325817D0 (en) * 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
ATE500276T1 (de) 2004-12-30 2011-03-15 Us Gov Health & Human Serv Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
RU2445366C2 (ru) 2007-09-28 2012-03-20 Чугаи Сейяку Кабусики Кайся Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
MX2010014079A (es) 2008-06-20 2011-02-22 Novartis Ag Inmunoglobulinas con agregacion reducida.
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
SG178340A1 (en) 2012-03-29
EP2467400A1 (en) 2012-06-27
CN102596994A (zh) 2012-07-18
MX2012002100A (es) 2012-06-19
TW201116626A (en) 2011-05-16
GB0914691D0 (en) 2009-09-30
US20150104449A1 (en) 2015-04-16
SG10201404903XA (en) 2014-10-30
JP2013502402A (ja) 2013-01-24
IL217993A0 (en) 2012-03-29
EP2467400B1 (en) 2018-01-24
AU2010284841A1 (en) 2012-03-15
US8951516B2 (en) 2015-02-10
CN106986935A (zh) 2017-07-28
JP5901522B2 (ja) 2016-04-13
DK2467400T3 (en) 2018-05-14
EA201290063A1 (ru) 2012-12-28
CA2771465A1 (en) 2011-02-24
WO2011021009A1 (en) 2011-02-24
US9290563B2 (en) 2016-03-22
US20120148568A1 (en) 2012-06-14
KR20120056850A (ko) 2012-06-04

Similar Documents

Publication Publication Date Title
BR112012003571A2 (pt) método para melhorar e para avaliar a capacidade de fabricação de uma imunoglobina, método para preparar uma imunoglobulina, e, imunoglobulina variante.
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BRPI0814466A2 (pt) Método.
BRPI1014035A2 (pt) método para contracepção.
BR112012022433A2 (pt) Método para fabricação de um transdutor de dobra, uma microbomba e uma microválvula, microbomba e microválvula
BR112012000171A2 (pt) composição lubrificante, e, método
BR112014005411A2 (pt) invólucro de cilindro, e método para fabricar o mesmo
BRPI0813569A2 (pt) Método de inspeção.
BR112014028447A2 (pt) bolsa coletora, e, método para fabricar uma bolsa coletora.
BRPI1014710A2 (pt) equipamento para a formação de uma montagem de janela de veículo, e método para a formação de uma montagem de janela de veículo.
BRPI0910950A2 (pt) haste de perfuração, e, método para fabricar uma haste de perfuração
BRPI0924664A2 (pt) eletrodo ,e ,método para construir um eletrodo.
BRPI1011186A2 (pt) contas expandíveis, corpo moldado, e, método de produção para o mesmo
BRPI1008304A2 (pt) pistão, e, método para construir um pistão
EP2586761A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUORPROPES
BRPI0823031A2 (pt) Conjunto, e , método para fabricar um conjunto
BRPI0815796A2 (pt) Compósito elastomérico e método para produzi-lo.
BRPI1001271A2 (pt) método para fabricar uma mídia de gravação óptica, e, mídia de gravação óptica.
BRPI1011531A2 (pt) composto, e , método para fluoração de 18f.
BRPI0918258A2 (pt) recipiente de embalagem, combinação de recipiente de embalagem, método para formação de cecipiente de embalagem e peça matriz
BR112012021236A2 (pt) método para produzir composição de isocianato modificada por uretonimina, e, composição de isocianato modificada por uretonimina
EP2474516A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUORPROPES
BR112013030538A2 (pt) conjunto de pistão e método para formar o mesmo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]